| Description |
Recombinant Mouse CLEC9A Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains Lys57-Ile264. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
NP_001192292.1 |
| Target Symbol |
CLEC9A |
| Synonyms |
CD370; CLEC9A; 9830005G06Rik; DNGR-1; HEEE9341; UNQ9341 |
| Species |
Mouse |
| Expression System |
HEK293 |
| Tag |
N-hFc |
| Expression Range |
Lys57-Ile264 |
| Mol. Weight |
The protein has a predicted MW of 50.9 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A() cells were in close proximity to TUNEL() cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients. |
